Sagimet Biosciences Files 8-K Report

Ticker: SGMT · Form: 8-K · Filed: May 23, 2024 · CIK: 1400118

Sentiment: neutral

Topics: 8-K, disclosure, financials

TL;DR

Sagimet Biosciences filed an 8-K on 5/23/24 for Reg FD and financials. Check it out.

AI Summary

On May 23, 2024, Sagimet Biosciences Inc. filed an 8-K report. The filing primarily concerns Regulation FD Disclosure and Financial Statements and Exhibits. The company, formerly known as 3-V Biosciences, Inc., is incorporated in Delaware and headquartered in San Mateo, California.

Why It Matters

This 8-K filing indicates that Sagimet Biosciences is providing updates related to its financial statements and exhibits, which could contain important information for investors regarding the company's financial health and operational status.

Risk Assessment

Risk Level: low — This filing is a standard 8-K report for disclosures and exhibits, not indicating any immediate material adverse events.

Key Numbers

Key Players & Entities

FAQ

What specific financial statements or exhibits are being disclosed in this 8-K filing?

The filing indicates 'Financial Statements and Exhibits' are included, but the specific details of these documents are not provided in the excerpt.

What is the significance of the 'Regulation FD Disclosure' item?

Regulation FD (Fair Disclosure) ensures that material information is disclosed to all investors simultaneously, suggesting this filing may contain such information.

When was Sagimet Biosciences Inc. formerly known as 3-V Biosciences, Inc. and when did the name change occur?

The filing states the former company name was 3-V Biosciences, Inc., and the date of the name change was May 21, 2007.

What is the primary business of Sagimet Biosciences Inc. based on its SIC code?

Sagimet Biosciences Inc. is classified under SIC code 2834, which corresponds to 'Pharmaceutical Preparations'.

Where are Sagimet Biosciences Inc.'s principal executive offices located?

The principal executive offices of Sagimet Biosciences Inc. are located at 155 Bovet Road, Suite 303, San Mateo, California 94402.

Filing Stats: 541 words · 2 min read · ~2 pages · Grade level 10.7 · Accepted 2024-05-23 07:00:24

Key Financial Figures

Filing Documents

01

Item 7.01 Regulation FD Disclosure On May 23, 2024, Sagimet Biosciences Inc. (the "Company"), updated information reflected in a slide presentation, which is attached as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference. Representatives of the Company will use the updated presentation in various meetings with investors from time to time. The information in Item 7.01 of this Current Report on Form 8-K, including the information set forth in Exhibit 99.1, is being furnished and shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), nor shall Exhibit 99.1 furnished herewith be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such a filing.

Financial Statements and Exhibits

Financial Statements and Exhibits (d) Exhibits Exhibit No. Document 99.1 Investor Presentation of Sagimet Biosciences Inc., dated May 23 , 2024 104 Cover Page Interactive Data File (embedded within the Inline XBRL document). SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Sagimet Biosciences Inc. Date: May 23 , 2024 By: /s/ David Happel David Happel Chief Executive Officer

View Full Filing

View this 8-K filing on SEC EDGAR

View on Read The Filing